Amplia Therapeutics Ltd
ASX:ATX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AU Optronics Corp
OTC:AUOTY
|
TW |
Amplia Therapeutics Ltd
Total Equity
Amplia Therapeutics Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amplia Therapeutics Ltd
ASX:ATX
|
Total Equity
AU$42.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
See Also
What is Amplia Therapeutics Ltd's Total Equity?
Total Equity
42.9m
AUD
Based on the financial report for Sep 30, 2025, Amplia Therapeutics Ltd's Total Equity amounts to 42.9m AUD.
What is Amplia Therapeutics Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
29%
Over the last year, the Total Equity growth was 236%. The average annual Total Equity growth rates for Amplia Therapeutics Ltd have been 31% over the past three years , 29% over the past five years .
